Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease ConferenceGlobeNewsWire • 09/30/21
Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine CandidateBenzinga • 09/28/21
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine CandidateGlobeNewsWire • 09/28/21
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001GlobeNewsWire • 09/23/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNewsfile Corp • 09/21/21
Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 VaccineGlobeNewsWire • 08/23/21
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine CandidateGlobeNewsWire • 08/11/21
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 08/05/21
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine CandidateGlobeNewsWire • 07/19/21
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor RelationsGlobeNewsWire • 07/06/21
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious DiseasesGlobeNewsWire • 07/05/21
Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine CandidateGlobeNewsWire • 07/01/21